HK1254030A1 - 治疗自身免疫病症和同种免疫病症的方法 - Google Patents

治疗自身免疫病症和同种免疫病症的方法 Download PDF

Info

Publication number
HK1254030A1
HK1254030A1 HK18112887.1A HK18112887A HK1254030A1 HK 1254030 A1 HK1254030 A1 HK 1254030A1 HK 18112887 A HK18112887 A HK 18112887A HK 1254030 A1 HK1254030 A1 HK 1254030A1
Authority
HK
Hong Kong
Prior art keywords
methods
individual
treating autoimmune
alloimmune
present disclosure
Prior art date
Application number
HK18112887.1A
Other languages
English (en)
Chinese (zh)
Inventor
格雷汉姆‧帕里
格雷漢姆‧帕里
帕维尔‧A‧尼基廷
桑迪普‧帕尼克
帕維爾‧A‧尼基廷
Original Assignee
比奥贝拉蒂美国公司
比奧貝拉蒂美國公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比奥贝拉蒂美国公司, 比奧貝拉蒂美國公司 filed Critical 比奥贝拉蒂美国公司
Publication of HK1254030A1 publication Critical patent/HK1254030A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18112887.1A 2015-06-26 2016-06-23 治疗自身免疫病症和同种免疫病症的方法 HK1254030A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562185362P 2015-06-26 2015-06-26
US62/185,362 2015-06-26

Publications (1)

Publication Number Publication Date
HK1254030A1 true HK1254030A1 (zh) 2019-07-12

Family

ID=57585852

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18112887.1A HK1254030A1 (zh) 2015-06-26 2016-06-23 治疗自身免疫病症和同种免疫病症的方法

Country Status (12)

Country Link
US (3) US20180169240A1 (cg-RX-API-DMAC7.html)
EP (1) EP3313417A4 (cg-RX-API-DMAC7.html)
JP (1) JP6963509B2 (cg-RX-API-DMAC7.html)
KR (1) KR20180020296A (cg-RX-API-DMAC7.html)
CN (1) CN108348600A (cg-RX-API-DMAC7.html)
AU (2) AU2016282782A1 (cg-RX-API-DMAC7.html)
CA (1) CA2990662A1 (cg-RX-API-DMAC7.html)
EA (1) EA038567B1 (cg-RX-API-DMAC7.html)
HK (1) HK1254030A1 (cg-RX-API-DMAC7.html)
IL (1) IL256424B2 (cg-RX-API-DMAC7.html)
MX (2) MX2017016835A (cg-RX-API-DMAC7.html)
WO (1) WO2016210172A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CA2965652A1 (en) 2016-04-29 2017-10-29 Pfizer Inc. Interferon beta antibodies
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
EP4696320A2 (en) 2019-05-15 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibody
CA3153207A1 (en) * 2019-10-16 2021-04-22 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
CN120757653A (zh) 2021-07-13 2025-10-10 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
JP4601426B2 (ja) * 2002-09-06 2010-12-22 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体成分ｃ５に対する抗体を使用する喘息の処置の方法
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
CA2720682A1 (en) * 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
CA2766565A1 (en) * 2009-06-23 2010-12-29 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
EP3722320A3 (en) * 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) * 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf

Also Published As

Publication number Publication date
NZ738570A (en) 2025-05-02
IL256424B2 (en) 2024-09-01
MX2023002021A (es) 2023-03-15
BR112017027578A2 (pt) 2018-08-28
AU2016282782A1 (en) 2018-01-18
IL256424A (en) 2018-02-28
EP3313417A1 (en) 2018-05-02
IL256424B1 (en) 2024-05-01
CN108348600A (zh) 2018-07-31
KR20180020296A (ko) 2018-02-27
EP3313417A4 (en) 2019-06-12
US20180169240A1 (en) 2018-06-21
MX2017016835A (es) 2018-08-01
EA201890106A1 (ru) 2018-05-31
JP6963509B2 (ja) 2021-11-10
JP2018526330A (ja) 2018-09-13
US20250295768A1 (en) 2025-09-25
AU2022215307B2 (en) 2025-09-04
EA038567B1 (ru) 2021-09-15
WO2016210172A1 (en) 2016-12-29
CA2990662A1 (en) 2016-12-29
US20220249664A1 (en) 2022-08-11
AU2022215307A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
HK1254030A1 (zh) 治疗自身免疫病症和同种免疫病症的方法
HK1222780A1 (zh) 具有微流体系统的眼科镜片
WO2016073380A8 (en) Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
HK1250752A1 (zh) 治疗骨髓增生性障碍的方法
EP2959280A4 (en) METHOD FOR LANGUAGE DECODING OF THE BRAIN AND SYSTEMS FOR CARRYING OUT THEREOF
EP3352843A4 (en) SYSTEMS AND METHOD FOR PERIPHERAL NERVE STIMULATION IN THE FINGER OR IN THE HAND TO TREAT HAND TREMORES
HK1250238A1 (zh) 抗angptl8抗体及其用途
EP2957336A3 (en) Methods for increasing the capacity of flow-through processes
MX2015017807A (es) Sistema cerrado integrado de extraccion de linea intravenosa.
WO2015153864A3 (en) Methods for treating inflammatory conditions
MX2017015758A (es) Componente de dispositivo, dispositivo, y metodo para purificar y ensayar biomoleculas de muestras biologicas.
WO2016063068A3 (en) Method and apparatus for the analysis of compounds
MX388168B (es) Un anticuerpo anti-amiloide beta (a?) monoclonal humanizado para usarse en el tratamiento de enfermedad de alzheimer.
WO2016012285A3 (en) Method
WO2015127134A3 (en) Complement component c5 antibodies
WO2013142796A3 (en) Methods of treatments using ctla4 antibodies
WO2008090360A8 (en) Methods
EA201790769A1 (ru) Определение уровней гликозаминогликанов методом масс-спектрометрии
EP3361263A4 (en) SAMPLE TREATMENT SCHIP, SAMPLE TREATMENT METHOD AND SAMPLE TREATMENT METHOD
CA2863417A1 (en) Innate immune proteins as biomarkers for cns injury
WO2017024019A8 (en) Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
MX2021013459A (es) Medicion rapida de la tasa de sedimentacion de los componentes sanguineos formados a partir de peque?os volumenes de muestra.
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
WO2016030334A3 (en) Methods, agents and compositions for treatment of inflammatory conditions